10 reports of this reaction
2.0% of all FLUDEOXYGLUCOSE F 18 reports
#8 most reported adverse reaction
BONE MARROW FAILURE is the #8 most commonly reported adverse reaction for FLUDEOXYGLUCOSE F 18, manufactured by Biomedical Research Foundation of Northwest Louisiana. There are 10 FDA adverse event reports linking FLUDEOXYGLUCOSE F 18 to BONE MARROW FAILURE. This represents approximately 2.0% of all 510 adverse event reports for this drug.
Patients taking FLUDEOXYGLUCOSE F 18 who experience bone marrow failure should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
BONE MARROW FAILURE is a less commonly reported adverse event for FLUDEOXYGLUCOSE F 18, but still significant enough to appear in the safety profile.
In addition to bone marrow failure, the following adverse reactions have been reported for FLUDEOXYGLUCOSE F 18:
BONE MARROW FAILURE has been reported as an adverse event in 10 FDA reports for FLUDEOXYGLUCOSE F 18. This does not prove causation, but indicates an association observed in post-market surveillance data.
BONE MARROW FAILURE accounts for approximately 2.0% of all adverse event reports for FLUDEOXYGLUCOSE F 18, making it a notable side effect.
If you experience bone marrow failure while taking FLUDEOXYGLUCOSE F 18, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.